Respiratory And Thoracic Cancers

Imfinzi Approved to Treat Stage III Non-Small Cell Lung Cancer

By February 20, 2018

The approval of Imfinzi is based on the positive PFS data from the Phase 3 PACIFIC trial.

Does Drinking Hot Tea Increase Esophageal Cancer Risk?

February 06, 2018

Compared with hot tea drinking alone, hot tea drinking combined with either alcohol consumption or smoking was associated with increased risk for esophageal cancer.

How E-Cigarette Smoke May Damage DNA, Inhibit Repair

January 30, 2018

"These results indicate that nicotine nitrosation occurs in vivo in mice and that e-cigarette smoke is carcinogenic to the murine lung and bladder and harmful to the murine heart," the authors write.

FDA Approves Expanded Indication for Gilotrif in NSCLC

By January 16, 2018

To determine if a patient is eligible for Gilotrif, physicians must conduct biomarker testing to determine the type of EGFR mutation present.

Risk-based lung cancer screening may prevent more deaths than current guidelines

January 12, 2018

In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency.

Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial

January 11, 2018

Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC).

Single Fluorouracil Course Examined for Preventing Squamous Cell CA

January 05, 2018

The researchers found that over four years, 299 patients developed a basal cell carcinoma end point and 108 developed a squamous cell carcinoma end point.

Lung Cancer Screening: Risk-Based Versus USPSTF Criteria Compared

January 04, 2018

Risk targeting may improve screening efficiency, but gains attenuated in terms of QALYs, cost

Cancer Drug Linked to Drastic Depletion of HIV Reservoirs

December 04, 2017

Case report describes smoker with HIV infection receiving nivolumab for non-small-cell lung cancer

Erlotinib Overdose May Lead to Rapid Onset of Ocular Toxicity

November 17, 2017

Findings in case study of man being treated for non-small-cell lung cancer

Alecensa Approved as First-Line Tx in ALK-Positive Metastatic NSCLC

By November 06, 2017

The approval was based on the Phase 3 ALEX study which evaluated the safety and efficacy of Alecensa versus crizotinib in patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease and whose tumors were characterized as ALK-positive by the VENTANA ALK CDx Assay.

Ready-to-Dilute Pemetrexed Formulation Gets Tentative FDA Approval

By October 30, 2017

Formulation does not require reconstitution, reducing the potential for dosing errors

CHEST: New Lung Cancer Screening Guidelines

By October 26, 2017

The manuscript has been submitted to CHEST for publication and findings will be presented at the CHEST 2017 Annual Meeting.

FDA Approves New Alunbrig Tablet Strength

By October 03, 2017

The FDA granted accelerated approval of Alunbrig, a kinase inhibitor, for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Do Checkpoint Inhibitors Carry Endocrine Dysfunction Risk?

September 29, 2017

Combination does not increase immune-related adverse events in metastatic lung cancer patients

First Biosimilar For Cancer Treatment Approved

By September 14, 2017

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.

Survival Rates Compared for Durvalumab vs. Placebo in NSCLC

September 11, 2017

A significantly higher response rate was seen with durvalumab versus placebo (28.4 versus 16.0%), with a longer median duration of response (72.8 versus 46.8% of patients had ongoing response at 18 months).

Long Term Vitamin Use Tied to Significant Increase in Cancer Risk

By August 24, 2017

Upon evaluation of the 10-year average supplement dose, it was found that lung cancer risk increased almost 2-fold in men taking >20mg/day of vitamin B6 (HR: 1.82; 95% CI: 1.25, 2.65) and >55mg/day of vitamin B12 (HR: 1.98; 95% CI: 1.32, 2.97) versus nonusers.

Cancer Survival for Alternative vs. Usual Treatment Examined

August 18, 2017

Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).

Tesevatinib Gains Orphan Drug Status for EGFR-Mutation Positive NSCLC

By August 07, 2017

In March 2016, tesevatinib was designated Orphan Drug status for the treatment of autosomal recessive polycystic kidney disease (ARPKD).

Imfinzi Designated Breakthrough Therapy for NSCLC

By July 31, 2017

Imfinzi, an anti-PD-L1 monoclonal antibody, was previously granted accelerated approval from the FDA for locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Regular Thyroxine Use May Raise Thyroid Cancer Risk

July 31, 2017

Compared with controls, cases were more likely to have been previously diagnosed with hypothyroidism (adjusted odds ratio, 3.01).

FDA Approves Combo Tx for Metastatic NSCLC with BRAF V600E Mutation

By June 23, 2017

The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.

Progression Free Survival with Nivolumab in Recurrent NSCLC

June 22, 2017

The researchers found that the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy among the 423 patients with a PD-L1 expression level of 5% or more.

Two New Meds May Improve Advanced NSCLC Survival Rates

June 06, 2017

The second clinical trial compared dacomitinib to the current standard targeted drug gefitinib in treating epidermal growth factor receptor-positive NSCLC.

Zykadia Approved for First-Line ALK-Positive Metastatic NSCLC

By May 30, 2017

The FDA approval was based on data from the Phase 3, open-label, randomized, multicenter, global ASCEND-4 trial.

Findings 'Strongly Suggest' Cigarette Filters Behind Rise in Lung CA

May 23, 2017

The new report recommends that the U.S. Food and Drug Administration should consider a ban on ventilating filters.

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

FDA Approves Keytruda Combo Tx for First-Line NSCLC

By May 11, 2017

The approval marks Keytruda as the only anti-PD-1 agent approved in the first-line setting as both monotherapy and combination therapy for appropriate patients with metastatic NSCLC.

Progression Free Survival in NSCLC Assessed With Selumetinib Addition

May 10, 2017

For selumetinib + docetaxel and placebo + docetaxel, median progression-free survival was 3.9 and 2.8 months, respectively.